Skip to main content
All articles

Announcement

Amavita Research Is GCSA-Recertified (May 13, 2026)

Independent assessment confirms continued operational excellence across all 7 modules of the global quality standard for clinical research sites.

Published May 13, 2026 3 min read

Amavita Research is GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027) by IAOCR — the International Accrediting Organization for Clinical Research. The certification confirms that Amavita Research meets the global quality standard for clinical research sites across all 7 business operational areas of the GCSA V5 2024 standard.

What GCSA is

The Global Clinical Site Assessment (GCSA) is the global quality standard for clinical research sites, developed by IAOCR in consultation with sponsors, CROs, public health trial sites, and government organizations. It validates a site's capability through independent assessment against sponsor-defined quality standards. GCSA certification assures sponsors and CROs of operational excellence across the full clinical trial lifecycle.

Certification assessment results

Amavita Research met all 7 modules of the GCSA V5 2024 standard:

  • Governance and Leadership
  • Growth and Strategy
  • Workforce Quality
  • Participant Engagement
  • Feasibility
  • Study Start-Up and Initiation
  • Study Management, Operations and Close Down

Areas exceeding standards

The assessment specifically called out two areas where Amavita Research exceeded the GCSA standard:

"A strong commitment to positive participant experiences is evident across the organisation, with staff demonstrating a clear understanding of how this is supported through site procedures and workplace culture. This commitment extends beyond formal policies and is reflected in a shared ethos among staff, strengthening its consistency and impact in practice."
— IAOCR GCSA Final Report
"A clear and well-defined focus on business development for 2026 is evident. Notable progress has been achieved through the appointment of a new Principal Investigator with expertise in a new therapeutic area (electrophysiology) and access to a new patient population, strengthening the organisation's clinical capabilities and expanding its research offering. In addition, the appointment of a new Head of Growth and Strategy further reinforces the organisation's capacity to deliver its development objectives, supporting a more structured approach to growth and positioning the organisation for future expansion."
— IAOCR GCSA Final Report

What this means for sponsors

For sponsors evaluating cardiovascular clinical trial sites, GCSA certification is independent third-party validation that Amavita Research's quality systems, workforce, study operations, and patient engagement meet the global standard. The assessment recognized operational maturity, including the expansion into cardiac electrophysiology under Dr. Hans C. Rutzen-Lopez and the appointment of Julio G. Martinez-Clark as Chief Executive Officer (CEO).

About IAOCR

IAOCR — the International Accrediting Organization for Clinical Research — develops and administers global quality standards for clinical research workforce and sites. Learn more at www.iaocr.com.

Related links

Next step

Evaluating Amavita Research for your cardiovascular trial?

See the full certification details and assessment scope, or send your protocol synopsis for a prompt response.

By Amavita Research · Published May 13, 2026. This announcement is sponsor-facing communication and is not medical advice.